Touyun Biotech Schedules 28 Aug 2026 Board Meeting to Approve 1H26 Results and Mull Interim Dividend

Bulletin Express

Aug 14

Touyun Biotech Group Limited will convene its board of directors on 28 August 2026 in Hong Kong. The agenda includes approval of the consolidated interim results for the six months ended 30 June 2026 and deliberation on a potential interim dividend.

The company’s board presently comprises nine members: three executive directors (Chairman Wang Liang, Vice Chairlady Zhou Ruijuan and Du Dong), three non-executive directors (Chen Hui, Tian Yuze and Zhang Lele) and three independent non-executive directors (Cheung Wing Ping, Ha Kee Choy Eugene and To Shing Chuen).

The announcement was authorised for issue by Chairman Wang Liang on 14 August 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/1190549953"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1190549953\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1190549953?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-14 17:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1190549953","market":"hk","top_or_hot":-1,"title":"Touyun Biotech Schedules 28 Aug 2026 Board Meeting to Approve 1H26 Results and Mull Interim Dividend","media":"Bulletin Express","content":"<p>Touyun Biotech Group Limited will convene its board of directors on 28 August 2026 in Hong Kong. The agenda includes approval of the consolidated interim results for the six months ended 30 June 2026 and deliberation on a potential interim dividend.</p>\n<p>The company’s board presently comprises nine members: three executive directors (Chairman Wang Liang, Vice Chairlady Zhou Ruijuan and Du Dong), three non-executive directors (Chen Hui, Tian Yuze and Zhang Lele) and three independent non-executive directors (Cheung Wing Ping, Ha Kee Choy Eugene and To Shing Chuen).</p>\n<p>The announcement was authorised for issue by Chairman Wang Liang on 14 August 2026.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Touyun Biotech Schedules 28 Aug 2026 Board Meeting to Approve 1H26 Results and Mull Interim Dividend</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTouyun Biotech Schedules 28 Aug 2026 Board Meeting to Approve 1H26 Results and Mull Interim Dividend\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-08-14 17:25</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Touyun Biotech Group Limited will convene its board of directors on 28 August 2026 in Hong Kong. The agenda includes approval of the consolidated interim results for the six months ended 30 June 2026 and deliberation on a potential interim dividend.</p>\n<p>The company’s board presently comprises nine members: three executive directors (Chairman Wang Liang, Vice Chairlady Zhou Ruijuan and Du Dong), three non-executive directors (Chen Hui, Tian Yuze and Zhang Lele) and three independent non-executive directors (Cheung Wing Ping, Ha Kee Choy Eugene and To Shing Chuen).</p>\n<p>The announcement was authorised for issue by Chairman Wang Liang on 14 August 2026.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01332","symbol_name":"透云生物","start_time":0,"source_url":"","article_id":"1190549953","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1190549953","pubTimestamp":1786699543,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Touyun Biotech Group Limited will convene its board of directors on 28 August 2026 in Hong Kong. The agenda includes approval of the consolidated interim results for the six months ended 30 June 2026...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01332":"透云生物"},"translate_title":"投云生物定于 2026 年 8 月 28 日召开董事会会议，批准 26 年上半年业绩并考虑中期股息","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01332":1},"content_text":"Touyun Biotech Group Limited will convene its board of directors on 28 August 2026 in Hong Kong. The agenda includes approval of the consolidated interim results for the six months ended 30 June 2026 and deliberation on a potential interim dividend.\nThe company’s board presently comprises nine members: three executive directors (Chairman Wang Liang, Vice Chairlady Zhou Ruijuan and Du Dong), three non-executive directors (Chen Hui, Tian Yuze and Zhang Lele) and three independent non-executive directors (Cheung Wing Ping, Ha Kee Choy Eugene and To Shing Chuen).\nThe announcement was authorised for issue by Chairman Wang Liang on 14 August 2026.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"dataReport,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}